WO2005114216A3 - Molecules d'acides nucleiques stamp2, polypeptides, et procedes diagnostiques et therapeutiques - Google Patents

Molecules d'acides nucleiques stamp2, polypeptides, et procedes diagnostiques et therapeutiques Download PDF

Info

Publication number
WO2005114216A3
WO2005114216A3 PCT/IB2005/001357 IB2005001357W WO2005114216A3 WO 2005114216 A3 WO2005114216 A3 WO 2005114216A3 IB 2005001357 W IB2005001357 W IB 2005001357W WO 2005114216 A3 WO2005114216 A3 WO 2005114216A3
Authority
WO
WIPO (PCT)
Prior art keywords
stamp2
polypeptides
nucleic acid
acid molecules
diagnostic
Prior art date
Application number
PCT/IB2005/001357
Other languages
English (en)
Other versions
WO2005114216A2 (fr
Inventor
Fahri Saatcioglu
Original Assignee
Biomedisinsk Innovasjon As
Fahri Saatcioglu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedisinsk Innovasjon As, Fahri Saatcioglu filed Critical Biomedisinsk Innovasjon As
Priority to PCT/IB2005/001357 priority Critical patent/WO2005114216A2/fr
Priority to CA002557053A priority patent/CA2557053A1/fr
Priority to AU2005246090A priority patent/AU2005246090A1/en
Publication of WO2005114216A2 publication Critical patent/WO2005114216A2/fr
Publication of WO2005114216A3 publication Critical patent/WO2005114216A3/fr
Priority to US11/453,608 priority patent/US7611892B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne de nouvelles molécules d'acides nucléiques STAMP2, des polypeptides, et des anticorps à utiliser dans des procédés pour diagnostiquer, traiter et prévenir des maladies et des états pathologiques de la prostate et des testicules, tels que le cancer.
PCT/IB2005/001357 2000-03-24 2005-02-22 Molecules d'acides nucleiques stamp2, polypeptides, et procedes diagnostiques et therapeutiques WO2005114216A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/IB2005/001357 WO2005114216A2 (fr) 2005-02-22 2005-02-22 Molecules d'acides nucleiques stamp2, polypeptides, et procedes diagnostiques et therapeutiques
CA002557053A CA2557053A1 (fr) 2004-02-19 2005-02-22 Molecules d'acides nucleiques stamp2, polypeptides, et procedes diagnostiques et therapeutiques
AU2005246090A AU2005246090A1 (en) 2005-02-22 2005-02-22 STAMP2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US11/453,608 US7611892B2 (en) 2000-03-24 2006-06-15 Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2005/001357 WO2005114216A2 (fr) 2005-02-22 2005-02-22 Molecules d'acides nucleiques stamp2, polypeptides, et procedes diagnostiques et therapeutiques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/453,608 Continuation-In-Part US7611892B2 (en) 2000-03-24 2006-06-15 Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods

Publications (2)

Publication Number Publication Date
WO2005114216A2 WO2005114216A2 (fr) 2005-12-01
WO2005114216A3 true WO2005114216A3 (fr) 2006-04-06

Family

ID=35429002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001357 WO2005114216A2 (fr) 2000-03-24 2005-02-22 Molecules d'acides nucleiques stamp2, polypeptides, et procedes diagnostiques et therapeutiques

Country Status (3)

Country Link
AU (1) AU2005246090A1 (fr)
CA (1) CA2557053A1 (fr)
WO (1) WO2005114216A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2008137075A2 (fr) * 2007-05-02 2008-11-13 President And Fellows Of Harvard College Compositions et procédés pour le traitement de troubles métaboliques et d'une inflammation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040276A2 (fr) * 1999-12-06 2001-06-07 Agensys, Inc Nouveaux antigenes transmembranaires du type serpentin exprimes dans des cancers humains et utilisation de ces antigenes
WO2001072962A2 (fr) * 2000-03-24 2001-10-04 Fahri Saatcioglu Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique
WO2003009814A2 (fr) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Nouveaux genes, compositions, trousses et methodes d'identification, evaluation, prevention, et traitement du cancer de la prostate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040276A2 (fr) * 1999-12-06 2001-06-07 Agensys, Inc Nouveaux antigenes transmembranaires du type serpentin exprimes dans des cancers humains et utilisation de ces antigenes
WO2001072962A2 (fr) * 2000-03-24 2001-10-04 Fahri Saatcioglu Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique
WO2003009814A2 (fr) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Nouveaux genes, compositions, trousses et methodes d'identification, evaluation, prevention, et traitement du cancer de la prostate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KORKMAZ KEMAL S ET AL: "Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 27 SEP 2002, vol. 277, no. 39, 27 September 2002 (2002-09-27), pages 36689 - 36696, XP002361957, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
CA2557053A1 (fr) 2005-12-01
AU2005246090A1 (en) 2005-12-01
WO2005114216A2 (fr) 2005-12-01

Similar Documents

Publication Publication Date Title
WO2001072962A3 (fr) Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique
WO2007115045A3 (fr) Diagnostics et traitements de tumeurs
WO2007067992A3 (fr) Anticorps monoclonaux humains se liant au fucosyl-gm1, et procedes d'utilisation de l'anti-fucosyl-gm1
MX2008009886A (es) Anticuerpos que enlazan par-2.
WO2006028655A3 (fr) Genes, compositions, kits, et methodes pour identification, evaluation, prevention et therapie du cancer de la prostate
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
WO2005103081A3 (fr) Anticorps monoclonaux humains diriges contre cd20
WO2006089230A3 (fr) Anticorps monoclonaux humains diriges contre l'antigene d'enveloppe specifique de la prostate
WO2007109236A3 (fr) Empreintes digitales micro-arn pendant une mégacaryocytopoïese
WO2005014035A3 (fr) Utilisation de galactose oxydase pour la conjugaison chimique selective de molecules d'extraction a des proteines d'interet therapeutique
WO2007016548A3 (fr) Procedes et compositions a base de micro-arn pour le diagnostic, le pronostic et le traitement du cancer du sein
WO2006083971A3 (fr) Anticorps dr5 et utilisations de ceux-ci
WO2008136848A3 (fr) Nouveaux anticorps anti-notch3 et leur utilisation dans la détection et le diagnostic d'une maladie
WO2007084181A3 (fr) Molécules d'anticorps fv à chaîne unique bispécifiques et procédés d'utilisation de celles-ci
WO2010059969A3 (fr) Thérapie antiangiogenèse pour le traitement du cancer du sein
WO2004050707A3 (fr) Molecules de reconnaissance specifiques de tumeurs
WO2004067570A3 (fr) Diagnostic et traitement du cancer de la prostate
WO2008018642A3 (fr) Gènes et polypeptides associés à des cancers du sein
WO2009070294A3 (fr) Inhibition du récepteur de la protéine stimulant les macrophages (ron) et procédés de traitement
WO2008073899A3 (fr) Compositions associées à prrg4 et procédés d'utilisation de celles-ci dans des procédés de diagnostic de tumeur
WO2004106495A3 (fr) Compositions, kits et procedes d'identification, d'evaluation et de prevention, et therapie anticancereuse
WO2007000320A3 (fr) Procede pour le diagnostic de maladies rhumatismales
WO2006095086A3 (fr) Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
EP1742654A4 (fr) Anticorps anti-lfl2 pour le diagnostic, le pronostic et le traitement d'un cancer
WO2006029176A3 (fr) Antigenes du cancer du testicule

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11453608

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2557053

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005246090

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005736094

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005246090

Country of ref document: AU

Date of ref document: 20050222

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005246090

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 11453608

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05736094

Country of ref document: EP

Kind code of ref document: A2